Comprehensive optimization of a single-chain variable domain antibody fragment as a targeting ligand for a cytotoxic nanoparticle

References

• Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 1999; 51:691-743; PMID:10581328
   PubMed Web of Science ®Google Scholar
• Drummond DC, Noble CO, Hayes ME, Park JW, Kirpotin DB. Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development. J Pharm Sci 2008; 97:4696-740; PMID:18351638
   PubMed Web of Science ®Google Scholar
• Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev 2013; 65:36-48; PMID:23036225; http://dx.doi.org/10.1016/j.addr.2012.09.037
   PubMed Web of Science ®Google Scholar
• Sparano JA, Malik U, Rajdev L, Sarta C, Hopkins U, Wolff AC. Phase I trial of pegylated liposomal doxorubicin and docetaxel in advanced breast cancer. J Clin Oncol 2001; 19:3117-25; PMID:11408509
   PubMed Web of Science ®Google Scholar
• Gaitanis A, Staal S. Liposomal doxorubicin and nab-paclitaxel: nanoparticle cancer chemotherapy in current clinical use. Methods in Mol Biol 2010; 624:385-92; PMID:20217610; http://dx.doi.org/10.1007/978-1-60761-609-2_26
   PubMedGoogle Scholar
• Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001; 19:3312-22; PMID:11454878
   PubMed Web of Science ®Google Scholar
• Socinski MA, Bondarenko I, Karaseva NA, Anatoly M. Makhson AM, Vynnychenko I, Okamoto I, Hon JK, Hirsh V, Bhar P, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small cell lung cancer: final results of a phase III trial. J Clin Oncol 2012; 30:2055-62; PMID:22547591; http://dx.doi.org/10.1200/JCO.2011.39.5848
   PubMed Web of Science ®Google Scholar
• Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M, O’Shaughnessy J. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005; 23:7794-803; PMID:16172456; http://dx.doi.org/10.1200/JCO.2005.04.937
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013; 369:1691-703; PMID:24131140; http://dx.doi.org/10.1056/NEJMoa1304369
   PubMed Web of Science ®Google Scholar
• Gill PS1, Wernz J, Scadden DT, Cohen P, Mukwaya GM, von Roenn JH, Jacobs M, Kempin S, Silverberg I, Gonzales G, et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol 1996; 14:2353-64; PMID:8708728
   PubMed Web of Science ®Google Scholar
• Orlowski RZ, Nagler A, Sonneveld P, Bladé J, Hajek R, Spencer A, Miguel JS, Robak T, Dmoszynska A, Horvath N, et al. Phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007; 25:3892-901; PMID:17679727; http://dx.doi.org/10.1200/JCO.2006.10.5460
   PubMed Web of Science ®Google Scholar
• Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale M, Connors JM, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 2012; 30:2190-6; PMID:22614995; http://dx.doi.org/10.1200/JCO.2011.38.0402
   PubMed Web of Science ®Google Scholar
• Krop IE, Kim SB, González-Martín A, LoRusso PM, Ferrero JM, Smitt M, Yu R, Leung AC, Wildiers H. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol 2014; 15:689-99; PMID:24793816; http://dx.doi.org/10.1016/S1470-2045(14)70178-0
   PubMed Web of Science ®Google Scholar
• Noble CO, Kirpotin DB, Hayes ME, Mamot C, Hong K, Park JW, Benz CC, Marks JD, Drummond DC. Development of ligand-targeted liposomes for cancer therapy. Expert Opin Ther Targets 2004; 8:335-53; PMID:15268628; http://dx.doi.org/10.1517/14728222.8.4.335
   PubMed Web of Science ®Google Scholar
• Koning GA, Morselt HWM, Gorter A, Allen TM, Zalipsky S, Scherphof GL, Kamps JAAM. Interaction of differently designed immunoliposomes with colon cancer cells and Kupffer cells. An in vitro comparison. Pharm Res 2003; 20:1249-57; PMID:12948023; http://dx.doi.org/10.1023/A:1025009300562
   PubMed Web of Science ®Google Scholar
• Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB, Marks JD, Benz CC, Park JW. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res 2006; 66:6732-40; PMID:16818648; http://dx.doi.org/10.1158/0008-5472.CAN-05-4199
   PubMed Web of Science ®Google Scholar
• Wang T, Duan Y. Probing the stability-limiting regions of an antibody single-chain variable fragment: a molecular dynamics simulation study. PEDS 2011; 24:649-57; PMID:21729946
   PubMed Web of Science ®Google Scholar
• Zemlin M, Klinger M, Link J, Zemlin C, Bauer K, Engler JA, Schroeder HW Jr, Kirkham PM. Expressed murine and human CDR-H3 intervals of equal length exhibit distinct repertoires that differ in their amino acid composition and predicted range of structures. J Mol Biol 2003; 334:733-49; PMID:14636599; http://dx.doi.org/10.1016/j.jmb.2003.10.007
   PubMed Web of Science ®Google Scholar
• Birtalan S, Zhang Y, Fellouse FA, Shao L, Schaefer G, Sidhu SS. The intrinsic contributions of tyrosine, serine, glycine and arginine to the affinity and specificity of antibodies. J Mol Biol 2008; 377:1518-28; PMID:18336836; http://dx.doi.org/10.1016/j.jmb.2008.01.093
   PubMed Web of Science ®Google Scholar
• Mian IS, Bradwell, AR, Olson AJ. Structure, function and properties of antibody binding sites. J Mol Biol 1991; 217:133-51; PMID:1988675; http://dx.doi.org/10.1016/0022-2836(91)90617-F
   PubMed Web of Science ®Google Scholar
• Wilkinson RA, Piscitelli C, Teintze M, Cavacini LA, Posner MR, Lawrence CM. Structure of the Fab fragment of F105, a broadly reactive anti-human immunodeficiency virus (HIV) antibody that recognizes the CD4 binding site of HIV type 1 gp120. J Virology 2005; vol:13060-69; PMID:16189008; http://dx.doi.org/10.1128/JVI.79.20.13060-13069.2005
   PubMed Web of Science ®Google Scholar
• Prassler J, Thiel S, Pracht C, Polzer A, Peters S, Bauer M, Nörenberg S, Stark Y, Kölln J, Popp A, et al. HuCAL PLATINUM, a synthetic Fab library optimized for sequence diversity and superior performance in mammalian expression systems. J Mol Biol 2011; 413:261-78; PMID:21856311; http://dx.doi.org/10.1016/j.jmb.2011.08.012
   PubMed Web of Science ®Google Scholar
• Barrett NA, Austen FK. Innate cells and T helper 2 cell immunity in airway inflammation. Immunity 2009; 31:425-37; PMID:19766085; http://dx.doi.org/10.1016/j.immuni.2009.08.014
   PubMed Web of Science ®Google Scholar
• Lavinder JJ, Hari SB, Sullivan BJ, Thomas J, Magliery TJ. High-throughput thermal scanning: a general, rapid dye-binding thermal shift screen for protein engineering. J Am Chem Soc 2009; 131:3794-95; PMID:19292479; http://dx.doi.org/10.1021/ja8049063
   PubMed Web of Science ®Google Scholar
• Nielsen UB, Kirpotin DB, Pickering EM, Drummond DC, Marks JD. A novel assay for monitoring internalization of nanocarrier coupled antibodies. BMC Immunol 2006; 7:24; PMID:17014727; http://dx.doi.org/10.1186/1471-2172-7-24
   PubMed Web of Science ®Google Scholar
• Ewert S1, Huber T, Honegger A, Plückthun A. Biophysical properties of human antibody variable domains. J Mol Biol 2003; 325:531-53; PMID:12498801; http://dx.doi.org/10.1016/S0022-2836(02)01237-8
   PubMed Web of Science ®Google Scholar
• Starovasnik MA1, O’Connell MP, Fairbrother WJ, Kelley RF. Antibody variable region binding by Staphylococcal protein A: thermodynamic analysis and location of the Fv binding site on E-domain. Protein Sci 1999; 8:1423-31; PMID:10422830; http://dx.doi.org/10.1110/ps.8.7.1423
   PubMed Web of Science ®Google Scholar
• Roben PW1, Salem AN, Silverman GJ. VH3 family antibodies bind domain D of staphylococcal protein A. J Immunol 1995;154:6437-45; PMID:7759880
   PubMed Web of Science ®Google Scholar
• Wörn A, Plückthun A. Stability engineering of antibody single-chain Fv fragments. J Mol Biol 2001; 305:989-1010; PMID:11162109; http://dx.doi.org/10.1006/jmbi.2000.4265
   PubMed Web of Science ®Google Scholar
• Jordan JL, Arndt JW, Hanf K, Li G, Hall J, Demarest S, Huang F, Wu X, Miller B, Glaser S, et al. Structural understanding of stabilization patterns in engineered bispecific Ig-like antibody molecules. Proteins 2009;77:832-41; PMID:19626705; http://dx.doi.org/10.1002/prot.22502
   PubMed Web of Science ®Google Scholar
• Benhar I, Pastan I. Identification of residues that stabilize the single-chain Fv of monoclonal antibodies B3. J Biol Chem 1995; 270:23373-80; PMID:7559495; http://dx.doi.org/10.1074/jbc.270.40.23373
   PubMed Web of Science ®Google Scholar
• McConnell AD, Spasojevich V, Macomber JL, Krapf IP, Chen A, Sheffer JC, Berkebile A, Horlick RA, Neben S, King DJ, et al. An integrated approach to extreme thermostabilization and affinity maturation of an antibody. Protein Eng Des Sel 2013; 26:151-64; PMID:23173178; http://dx.doi.org/10.1093/protein/gzs090
   PubMed Web of Science ®Google Scholar
• Yin S, Ding F, Dokholyan NV. Eris: an automated estimator of protein stability. Nat Methods 2007; 4:466-7; PMID:17538626; http://dx.doi.org/10.1038/nmeth0607-466
   PubMed Web of Science ®Google Scholar
• Alfthan K, Takkinen K, Sizmann D, Söderlund H, Teeri TT. Properties of a single-chain antibody containing different linker peptides. Protein Eng 1995; 8:725-31; PMID:8577701; http://dx.doi.org/10.1093/protein/8.7.725
   PubMedGoogle Scholar
• Huston JS1, Levinson D, Mudgett-Hunter M, Tai MS, Novotný J, Margolies MN, Ridge RJ, Bruccoleri RE, Haber E, Crea R, et al. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. PNAS USA 1988; 85:5879-83; PMID:3045807; http://dx.doi.org/10.1073/pnas.85.16.5879
   PubMed Web of Science ®Google Scholar
• Fellouse FA, Wiesmann C, Sidhu SS. Synthetic antibodies from a four-aminoacid code: a dominant role for tyrosine in antigen recognition. PNAS USA 2004; 101:12467-72; PMID:15306681; http://dx.doi.org/10.1073/pnas.0401786101
   PubMed Web of Science ®Google Scholar
• Perchiacca JM, Lee CC, Tessie PM. Optimal charged mutations in the complementarity-determining regions that prevent domain antibody aggregation are dependent on the antibody scaffold. PEDS 2014; 27:29-39; PMID:24398633
   PubMed Web of Science ®Google Scholar
• Dudgeon K, Rouet R, Kokmeijer I, Schofield P, Stolp J, Langley D, Stock D, Christ D. General strategy for the generation of human antibody variable domains with increased aggregation resistance. PNAS USA 2012; 109:10879-84; PMID:22745168; http://dx.doi.org/10.1073/pnas.1202866109
   PubMed Web of Science ®Google Scholar
• Weaver-Feldhaus JM, Miller KD, Feldhaus MJ, Siegel RW. Directed evolution for the development of conformation-specific affinity reagents using yeast display. PEDS 2005; 18: 527-36; PMID:16186140
   PubMed Web of Science ®Google Scholar
• Perchiacca JM, Lee CC, Tessier PM. Optimal charged mutations in the complementarity-determining regions that prevent domain antibody aggregation are dependent on the antibody scaffold. Protein Eng Des Sel 2014; 27:29-39; PMID:24398633; http://dx.doi.org/10.1093/protein/gzt058
   PubMed Web of Science ®Google Scholar
• Mian IS, Bradwell AR, und Olson AJ. Structure, function and properties of antibody binding sites. J Mol Biol 1991; 217:133-51; PMID:1988675; http://dx.doi.org/10.1016/0022-2836(91)90617-F
   PubMed Web of Science ®Google Scholar
• Wilkinson RA, Piscitelli C, Teintze M, Cavacini LA, Posner MR, Lawrence CM. Structure of the Fab fragment of F105, a broadly reactive anti-human immunodeficiency virus (HIV) antibody that recognizes the CD4 binding site of HIV type 1 gp120. J Virol 2005; 79:13060-9; PMID:16189008; http://dx.doi.org/10.1128/JVI.79.20.13060-13069.2005
   PubMed Web of Science ®Google Scholar
• Collis AV, Brouwer AP, Martin AC. Analysis of the antigen combining site: correlations between length and sequence composition of the hypervariable loops and the nature of the antigen. J Mol Biol 2003; 325:337-54; PMID:12488099; http://dx.doi.org/10.1016/S0022-2836(02)01222-6
   PubMed Web of Science ®Google Scholar
• Xu L, Kohli N, Rennard R, Jiao Y, Razlog M, Zhang K, Baum J, Johnson B, Tang J, Schoeberl B, et al. Rapid optimization and prototyping for therapeutic antibody-like molecules. MABS 2013; 5:237-54; PMID:23392215; http://dx.doi.org/10.4161/mabs.23363
   PubMed Web of Science ®Google Scholar
• Wang Q, Canutescu AA, Dunbrack RL. SCWRL and MolIDE: computer programs for side-chain conformation prediction and homology modeling. Nat Protoc 2008; 3:1832-47; PMID:18989261; http://dx.doi.org/10.1038/nprot.2008.184
   PubMed Web of Science ®Google Scholar
• Canutescu AA, Dunbrack RL. MollDE: a homology modeling framework you can click with. Bioinformatics 2005; 21:2914-16; PMID:15845657; http://dx.doi.org/10.1093/bioinformatics/bti438
   PubMed Web of Science ®Google Scholar
• Canutescu AA, Dunbrack RL. Cyclic coordinate descent: a robotics algorithm for protein loop closure. Protein Sci 2003; 12:963-72; PMID:12717019; http://dx.doi.org/10.1110/ps.0242703
   PubMed Web of Science ®Google Scholar
• Canutescu AA, Shelenkov AA, Dunbrack RL. A graph-theory algorithm for rapid protein side-chain prediction. Protein Sci 2003; 12:2001-14; PMID:12930999; http://dx.doi.org/10.1110/ps.03154503
   PubMed Web of Science ®Google Scholar
• Guex N, Peitsch MC. SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 1997; 18:2714-23; PMID:9504803; http://dx.doi.org/10.1002/elps.1150181505
   PubMed Web of Science ®Google Scholar
• Wu TT, Kabat EA, Bilofsky H. Some sequence similarities among cloned mouse DNA segments that code for lambda and kappa light chains of immunoglobulins. PNAS USA 1979; 76:4617-21; PMID:116235; http://dx.doi.org/10.1073/pnas.76.9.4617
   PubMed Web of Science ®Google Scholar